1. Home
  2. NRT vs IRD Comparison

NRT vs IRD Comparison

Compare NRT & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRT
  • IRD
  • Stock Information
  • Founded
  • NRT 1975
  • IRD 2018
  • Country
  • NRT United States
  • IRD United States
  • Employees
  • NRT N/A
  • IRD N/A
  • Industry
  • NRT Oil & Gas Production
  • IRD
  • Sector
  • NRT Energy
  • IRD
  • Exchange
  • NRT Nasdaq
  • IRD NYSE
  • Market Cap
  • NRT 44.0M
  • IRD 35.7M
  • IPO Year
  • NRT N/A
  • IRD N/A
  • Fundamental
  • Price
  • NRT $4.28
  • IRD $0.93
  • Analyst Decision
  • NRT
  • IRD Strong Buy
  • Analyst Count
  • NRT 0
  • IRD 1
  • Target Price
  • NRT N/A
  • IRD $8.00
  • AVG Volume (30 Days)
  • NRT 26.2K
  • IRD 141.6K
  • Earning Date
  • NRT 02-28-2025
  • IRD 03-25-2025
  • Dividend Yield
  • NRT 11.14%
  • IRD N/A
  • EPS Growth
  • NRT N/A
  • IRD N/A
  • EPS
  • NRT 0.56
  • IRD N/A
  • Revenue
  • NRT $5,942,748.00
  • IRD $8,381,000.00
  • Revenue This Year
  • NRT N/A
  • IRD N/A
  • Revenue Next Year
  • NRT N/A
  • IRD $29.37
  • P/E Ratio
  • NRT $7.60
  • IRD N/A
  • Revenue Growth
  • NRT N/A
  • IRD N/A
  • 52 Week Low
  • NRT $3.88
  • IRD $0.81
  • 52 Week High
  • NRT $8.62
  • IRD $2.34
  • Technical
  • Relative Strength Index (RSI)
  • NRT 41.99
  • IRD N/A
  • Support Level
  • NRT $4.16
  • IRD N/A
  • Resistance Level
  • NRT $4.46
  • IRD N/A
  • Average True Range (ATR)
  • NRT 0.20
  • IRD 0.00
  • MACD
  • NRT -0.03
  • IRD 0.00
  • Stochastic Oscillator
  • NRT 24.00
  • IRD 0.00

About NRT North European Oil Royality Trust

North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Share on Social Networks: